Conestat alfa is a recombinant human C1 esterase inhibitor (rhC1-INH), an intravenous anti-inflammatory drug with the potential to inhibit the complement and kallikrein-kinin cascades in severe COVID-19.
Recent:Urwyler.
Oct 27 2023 |
et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1255292 | Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial |
| 238% higher mortality (p=0.26), 286% higher ventilation (p=0.26), 141% higher ICU admission (p=0.32), and 117% lower hospital discharge (p=0.12). RCT 84 hospitalized COVID-19 patients showing higher mortality with conestat alfa (recombinant C1 inhibitor), without reaching statistical significance. | ||
Dec 1 2021 |
et al., NCT04530136 | Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US |
| 78% lower mortality (p=0.29), 87% lower ventilation (p=0.08), 46% lower progression (p=0.07), and 52% shorter hospitalization (p=0.06). RCT 38 hospitalized COVID-19 patients showing non-significant improvements with conestat alfa. Results of this manufacturer RCT are notably better than the non-manufacturer RCT [Urwyler]. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.